Skinvisible Inc (SKVI) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
6320 S SANDHILL ROAD LAS VEGAS, NV 89120 |
| State of Incorp. | NV |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 6/30/2025 MRQ | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 10 | 1 | 81 | 66 | 36 | 1 | |||
| Cash and cash equivalent | 10 | 1 | 81 | 66 | 36 | 1 | |||
| Receivables | 5 | 27 | 19 | 0 | 8 | 10 | |||
| Other undisclosed current assets | 27 | 8 | 9 | 8 | 7 | 5 | |||
| Total current assets: | 42 | 35 | 110 | 74 | 50 | 16 | |||
| Noncurrent Assets | |||||||||
| Intangible assets, net (including goodwill) | 116 | 127 | 137 | 153 | 150 | 165 | |||
| Intangible assets, net (excluding goodwill) | 116 | 127 | 137 | 153 | 150 | 165 | |||
| Total noncurrent assets: | 116 | 127 | 137 | 153 | 150 | 165 | |||
| TOTAL ASSETS: | 158 | 163 | 247 | 227 | 200 | 182 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 859 | 439 | 1,202 | 1,040 | 865 | 597 | |||
| Interest and dividends payable | ✕ | ✕ | ✕ | ✕ | 1,475 | 1,021 | 492 | ||
| Accrued liabilities | 2,785 | 2,576 | 1,956 | ||||||
| Other undisclosed accounts payable and accrued liabilities | (1,926) | (2,137) | (754) | (435) | (156) | 106 | |||
| Debt | 13 | 6 | |||||||
| Due to related parties | ✕ | ✕ | ✕ | 27 | 52 | 47 | |||
| Other undisclosed current liabilities | 2,807 | 3,068 | 2,443 | 1,994 | 1,801 | 2,545 | |||
| Total current liabilities: | 3,680 | 3,512 | 3,645 | 3,061 | 2,719 | 3,189 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 5,372 | 5,372 | 220 | ||||||
| Long-term debt, excluding current maturities | 5,372 | 5,372 | 220 | ||||||
| Other undisclosed noncurrent liabilities | 352 | 301 | 3,242 | 2,582 | 1,716 | ||||
| Total noncurrent liabilities: | 5,724 | 5,674 | 3,242 | 2,582 | 1,936 | ||||
| Total liabilities: | 9,404 | 9,186 | 6,887 | 5,643 | 4,655 | 3,189 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | (9,246) | (9,023) | (6,641) | (5,416) | (4,455) | (3,007) | |||
| Common stock | 5 | 5 | 5 | 5 | 5 | 4 | |||
| Additional paid in capital | 30,685 | 30,353 | 30,353 | 30,353 | 30,241 | 30,182 | |||
| Accumulated deficit | (39,946) | (39,380) | (36,998) | (35,773) | (34,700) | (33,253) | |||
| Other additional capital | 10 | ||||||||
| Other undisclosed equity, attributable to parent | 60 | ||||||||
| Total equity: | (9,246) | (9,023) | (6,641) | (5,416) | (4,455) | (3,007) | |||
| TOTAL LIABILITIES AND EQUITY: | 158 | 163 | 247 | 227 | 200 | 182 | |||
Income Statement (P&L) ($ in thousands)
| 6/30/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 20 | 20 | 279 | 663 | 153 | 43 | ||
| Revenue from related parties | ✕ | ✕ | ✕ | 123 | ||||
| Other income | (15) | |||||||
| Cost of revenue | (5) | (3) | (18) | |||||
| Cost of product and service sold | (10) | |||||||
| Other undisclosed gross profit | 123 | |||||||
| Gross profit: | 20 | 20 | 274 | 660 | 276 | 26 | ||
| Operating expenses | (610) | (510) | (513) | (472) | (529) | (565) | ||
| Other operating expense, net (Other Expenses) | (1,892) | (986) | (1,261) | (1,194) | (1,162) | |||
| Other undisclosed operating income | 1,892 | 986 | 1,261 | 1,194 | 1,162 | |||
| Operating income (loss): | (590) | (490) | (238) | 188 | (254) | (540) | ||
| Nonoperating income (Debt Instrument, Convertible, Beneficial Conversion Feature) | 3,649 | |||||||
| Interest and debt expense | 697 | (1,887) | (1,018) | (1,103) | (1,194) | (999) | ||
| Other undisclosed income from continuing operations before equity method investments, income taxes | ||||||||
| Income (loss) from continuing operations: | 108 | (2,378) | (1,257) | (915) | (1,448) | 2,111 | ||
| Income (loss) before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (915) | (1,448) | 2,111 | |
| Net income (loss): | 108 | (2,378) | (1,257) | (915) | (1,448) | 2,111 | ||
| Other undisclosed net income (loss) attributable to parent | (673) | (5) | 32 | (157) | (3,813) | |||
| Net loss available to common stockholders, diluted: | (566) | (2,382) | (1,225) | (1,073) | (1,448) | (1,702) | ||
Comprehensive Income ($ in thousands)
| 6/30/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | 108 | (2,378) | (1,257) | (915) | (1,448) | 2,111 | ||
| Comprehensive income (loss), net of tax, attributable to parent: | 108 | (2,378) | (1,257) | (915) | (1,448) | 2,111 | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.